Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (6684)	5/20/1999 11:38:00 PM
From: Bob L	Respond to of 9719

I looked at a bunch of NeoRx stuff and couldn't find any explanation of what they mean by "commercially available". It doesn't necessarily mean the same as "approved by FDA". However, I did sort of make a jump in assuming because they worked with NSC on the earlier Avicidan that they also are building their lymphoma one. All their stuff sort of implies that, except for the "commercially available" line. If they mean FDA approved, why the secrecy? (NeoRx frequently refers to it as the "humanized" antibody, without naming it.) We can all list the number of FDA approved lymphoma antibodies pretty easily .... a list of one. Could they mean commercially available in the sense it can be bought for and used for trials, if they get the trial approved?

To: scaram(o)uche who wrote (6684)	5/21/1999 1:48:00 AM
From: Bob L	Read Replies (1) \| Respond to of 9719

Ah, you are right, they are using rituxan. Here is a trial "Protocol IDs: VMRC-6249, NCI-V98-1471, NEORX-9802" cancernet.nci.nih.gov "Patients receive rituximab-streptavidin (C2B8-SA) conjugate IV that may be labeled with Rhenium-186. Prior to C2B8-SA conjugate, patients may receive rituximab IV. Patients are then given a clearing agent to remove unbound antibodies. All patients receive biotin conjugated to DOTA (DOTA-biotin) labelled with Indium-111 and with or without Yttrium-90. Patients who receive C2B8-SA conjugate labelled with Rhenium-186 will undergo gamma camera imaging studies prior to administration of the clearing agent."